GH Research PLC GHRS
At closeNov 10, 2026, 4:01 PM EST
After hours · Nov 10, 4:01 PM ET
- YTD
- +54.02%
- 1 year
- +44.46%
- Market cap
- 1.34B
- EPS (ttm)
- -0.99
- Shares out
- 68.64M
- Forward P/E
- -10.57
- YTD return
- +54.02%
- 1-year return
- +44.46%
- Volume
- 108.74K
- Avg volume
- 301.64K
- Open
- 19.04
- Previous close
- 19.26
- Day's range
- 18.83 – 19.85
- 52-week range
- 12.04 – 31.44
- Beta
- 1.32
- Price target
- 42.89 (+119.3%)
- Earnings date
- Mar 4, 2027
Key statistics
- Enterprise value
- 959.76M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 3.73
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -36.52M
- Total cash
- 362.65M
- Total debt
- 360.00K
- Return on equity
- -18.79%
- Short % of float
- 7.47%
- 50-day average
- 22.98
- 200-day average
- 21.64
Analyst view
- Target (low)
- 38.00
- Target (mean)
- 42.89
- Target (high)
- 65.00
- Strong buy3
- Buy7
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 4, 2027
Expected Mar 4, 2027. Consensus EPS estimate -0.30222.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 4, 2027 | Dec 30, 2026 | -0.36089 | — | — | — |
| Nov 9, 2026 | Sep 30, 2026 | -0.31216 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.286 | -0.23 | +0.06 | +19.58% |
| May 14, 2026 | Mar 31, 2026 | -0.27 | -0.31 | -0.04 | -14.81% |
| Mar 5, 2026 | Dec 31, 2025 | -0.29 | -0.23 | +0.06 | +20.69% |
| Nov 6, 2025 | Sep 30, 2025 | -0.23 | -0.23 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 2026 | Guggenheim | main | Buy | Buy |
| Aug 7, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
| Aug 6, 2026 | Needham | main | Buy | Buy |
| Jul 27, 2026 | Wells Fargo | init | — | Overweight |
| May 19, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| May 15, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
About GH Research PLC
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Ireland
- Website
- ghres.com
News
Guggenheim Maintains Buy on GH Research, Raises Price Target to $40 
Cantor Fitzgerald Maintains Overweight on GH Research, Raises Price Target to $40 
Needham Maintains Buy on GH Research, Raises Price Target to $39 - GH Research Q2 EPS $(0.23) Beats $(0.30) Estimate
Wells Fargo Initiates Coverage On GH Research with Overweight Rating, Announces Price Target of $44 
Why Is GH Research Stock Trading Higher on Thursday? 
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
GH Research Announces Publication Of Full Results From Its Phase 2a Trial In Postpartum Depression 
HC Wainwright & Co. Maintains Buy on GH Research, Lowers Price Target to $65 
These Analysts Revise Their Forecasts On GH Research After Q1 Results
Your note
Sign in to keep a note on GHRS — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Lynx1 Capital Management Lp | 19.33% | 13,263,288 | 259.43M | Jun 29, 2026 |
| BVF Inc. | 12.61% | 8,650,158 | 169.20M | Jun 29, 2026 |
| RA Capital Management, L.P. | 11.13% | 7,636,813 | 149.38M | Jun 29, 2026 |
| FMR, LLC | 8.71% | 5,977,045 | 116.91M | Jun 29, 2026 |
| RTW Investments LP | 8.65% | 5,933,815 | 116.07M | Jun 29, 2026 |
| Deep Track Capital, Lp | 4.86% | 3,333,334 | 65.20M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 3.07% | 2,104,309 | 41.16M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 0.93% | 637,540 | 12.47M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 0.72% | 493,500 | 9.65M | Sep 29, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.58% | 397,104 | 7.77M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 0.26% | 178,400 | 3.49M | Sep 29, 2026 |
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 0.13% | 92,038 | 1.80M | Oct 30, 2026 |